Ray Sheridan
Overview
Explore the profile of Ray Sheridan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Devos D, Rascol O, Meissner W, Foubert-Samier A, Lewis S, Tranchant C, et al.
J Parkinsons Dis
. 2025 Feb;
:1877718X241300295.
PMID: 39973479
Background: Reducing nigrostriatal iron overload reduces neuronal loss in Parkinson's disease (PD) models. Objective: Examine the safety and efficacy of deferiprone in reducing motor disability progression in dopaminergic-treated and treatment-naïve...
2.
Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt E, Laabs B, et al.
Brain
. 2024 Aug;
147(8):2652-2667.
PMID: 39087914
Estimates of the spectrum and frequency of pathogenic variants in Parkinson's disease (PD) in different populations are currently limited and biased. Furthermore, although therapeutic modification of several genetic targets has...
3.
Lee I, Cosgrove C, Moore P, Bethune C, Nally R, Bula M, et al.
Lancet Infect Dis
. 2023 Jun;
23(9):1007-1019.
PMID: 37348519
Background: The omicron BA.1 bivalent booster is used globally. Previous open-label studies of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising antibody responses against omicron BA.1 and other variants...
4.
Liu X, Munro A, Wright A, Feng S, Janani L, Aley P, et al.
J Infect
. 2023 Apr;
87(1):18-26.
PMID: 37085049
Background: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were...
5.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2023 Apr;
86(5):540-541.
PMID: 37055303
No abstract available.
6.
Munro A, Feng S, Janani L, Cornelius V, Aley P, Babbage G, et al.
Lancet Infect Dis
. 2022 May;
22(8):1131-1141.
PMID: 35550261
Background: Some high-income countries have deployed fourth doses of COVID-19 vaccines, but the clinical need, effectiveness, timing, and dose of a fourth dose remain uncertain. We aimed to investigate the...
7.
Liu X, Munro A, Feng S, Janani L, Aley P, Babbage G, et al.
J Infect
. 2022 Apr;
84(6):795-813.
PMID: 35405168
Objectives: To evaluate the persistence of immunogenicity three months after third dose boosters. Methods: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a...
8.
Munro A, Janani L, Cornelius V, Aley P, Babbage G, Baxter D, et al.
Lancet
. 2021 Dec;
398(10318):2258-2276.
PMID: 34863358
Background: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we...
9.
Bruce J, Hossain A, Lall R, Withers E, Finnegan S, Underwood M, et al.
Health Technol Assess
. 2021 Jun;
25(34):1-114.
PMID: 34075875
Background: Falls and fractures are a major problem. Objectives: To investigate the clinical effectiveness and cost-effectiveness of alternative falls prevention interventions. Design: Three-arm, pragmatic, cluster randomised controlled trial with parallel...
10.
Pearce J, Sheridan R, Shaw J, Senior T
BMJ Case Rep
. 2021 Mar;
14(3).
PMID: 33737274
This case demonstrates an atypical radiological presentation of cerebral toxoplasmosis in a 62-year-old HIV-positive patient. The diagnosis is discussed alongside MRI imaging, laboratory results and treatment. Central nervous system toxoplasmosis...